2024ÄêÅ·ÖÞÄÚ¿ÆÖ×Áöѧ»á£¨ESMO£©Äê»áÓÚµ±µØÊ±¼ä9ÔÂ13ÈÕÖÁ17ÈÕÔÚÎ÷°àÑÀ°ÍÈûÂÞÄÇÕÙ¿ª£¬µÏÍþÖÆµÏÍþ¹ú¼Ê´´ÐµÏÍþ¹ú¼Ê·úÂíÌæÄáÒÔ±Ú±¨ÐÎʽÁÁÏà±¾½ì´ó»á¡£¸ÃÑо¿ÓÉÖ£ÖÝ´óѧµÚÒ»¸½ÊôÒ½ÔºÍõÎÀÃô¡¢Ëï»Û½ÌÊÚÍŶÓǣͷ£¬·ÖÎöÁË·úÂíÌæÄáÁªºÏ¶àµÏÍþ¹ú¼Ê»¯ÁÆÔÚÒ»ÏßÖÎÁƷѳÇȾɫÌåÑôÐÔ¼±ÐÔÁܰÍϸ°û°×Ѫ²¡£¨Ph+ ALL£©»¼ÕßÖеÄÓÐЧÐÔ£¬ÎªPh+ ALL»¼ÕßÓ¦Ó÷úÂíÌæÄáÖÎÁÆÌṩÁËеÄÑ֤ҽѧ֤¾Ý¡£

·úÂíÌæÄáÊÇÖйúÊ׸öÔÑÐÂýÐÔËèÐÔ°×Ѫ²¡ÐÂÐͶþ´úTKI£¬ÒÑÔÚ¶àÏîÕë¶ÔÂýÐÔÁ£Ï¸°û°×Ѫ²¡£¨CML£©»¼ÕßµÄÁÙ´²Ñо¿ÖÐÏÔʾ³ö¿ÉϲµÄÁÆÐ§ºÍÁ¼ºÃµÄÄÍÊÜÐÔ£¬²¢ÇÒÔÚPh+ ALLÖÎÁÆÁìÓòÒ²ÏÔÏÖ³ö²»Ë×DZÁ¦¡£
Ph+ ALLÔÚ³ÉÈ˼±ÐÔÁܰÍϸ°û°×Ѫ²¡£¨ALL£©ÖÐÕ¼20%~30%£¬Ó¦Óô«Í³»¯ÁÆÐ§¹û²î£¬¶àµÏÍþ¹ú¼Ê»¯ÁƵÄ5ÄêÉú´æÂʵÍÓÚ20%¡£ÀÒ°±ËἤøÒÖÖÆ¼Á£¨TKI£©Ó¦ÓÃÓÚÒ»ÏßÖÎÁƺó£¬Ph+ ALL»¼ÕßµÄÔ¤ºóÓÐÁËÏÔÖøµÄ¸ÄÉÆ(1)(2)¡£

±¾Ñо¿(3)ΪһÏîµ¥ÖÐÐÄ¡¢»Ø¹ËÐÔ¹Û²ìÑо¿£¬¹²ÄÉÈëÁË48ÀýÓÚ2020Äê4ÔÂÖÁ2023Äê5ÔÂÆÚ¼ä½ÓÊÜ·úÂíÌæÄáÁªºÏ¶àµÏÍþ¹ú¼Ê»¯ÁÆ·½°¸ÖÎÁƵÄÐÂÕï¶ÏµÄ³ÉÈËPh+ ALL»¼Õߣ¬²¢Í¨¹ýµç×Ó²¡ÀúϵͳºÍµç»°Ëæ·ÃÖÁ2023Äê11ÔÂ14ÈÕ¡£
ÔÚ·úÂíÌæÄáÁªºÏ¶àµÏÍþ¹ú¼Ê»¯Áƺó£¬ÓÕµ¼µÄÍêÈ«»º½â£¨CR£©ÂÊÔÚ0.5¸öÔ¡¢1¸öÔ¡¢3¸öÔ¡¢6¸öÔ·ֱð´ïµ½100%¡¢97.9%¡¢100%ºÍ93.3%¡£Í¨¹ýÁ÷ʽϸ°ûÊõ¼ì²âµÄ΢С²ÐÁô²¡ÔîÒõÐÔ£¨MRD-£©ÂÊÔÚ0.5¸öÔ¡¢1¸öÔ¡¢3¸öÔºÍ6¸öÔÂʱ·Ö±ðΪ59.3%¡¢81.3%¡¢95.1%ºÍ90.0%¡£
ÖÐÎ»Ëæ·Ã41.1¸öÔ£¬3Äê×ÜÉú´æ£¨OS£©ÂÊ¡¢ÎÞ½øÕ¹Éú´æ£¨PFS£©ÂʺÍÎÞʼþÉú´æ£¨EFS£©ÂÊ·Ö±ðΪ70.8%¡¢62.5%ºÍ45.8%¡£35.42%µÄ»¼Õß½ÓÊÜÁËÒì»ùÒòÔìѪ¸Éϸ°ûÒÆÖ²£¨Allo-HSCT£©£¬½ÓÊÜAllo-HSCT»¼ÕßµÄOSÏÔÖøÓÅÓÚδ½ÓÊÜAllo-HSCTµÄ»¼Õß¡£
´ËÍ⣬ÓÕµ¼ÖÎÁƺó´ïµ½CR»¼ÕßµÄOSÏÔÖøÑÓ³¤£¬»ñµÃMRD-»¼ÕßµÄOSÏÔÖøÓÅÓÚMRD+»¼Õß¡£
ÓÉÉÏÊö½á¹û¿É¼û£¬·úÂíÌæÄáÁªºÏ¶àµÏÍþ¹ú¼Ê»¯ÁÆ×÷ΪÐÂÕï¶ÏPh+ ALL³ÉÄ껼ÕßµÄÓÕµ¼ÖÎÁÆ·½°¸ÁÆÐ§ÏÔÖø£¬ÓÐÍûΪÖйúPh+ ALL»¼Õß´øÀ´¸ü¶àÉú´æÏ£Íû¡£
²Î¿¼ÎÄÏ×£º
Á¬Ï¼Ó¢, ´÷º£Æ¼, ´ÞÇìÑÇ, µÈ. ·úÂíÌæÄáÁªºÏÓÕµ¼»¯ÁƲ¢Ðò¹áÒì»ùÒòÔìѪ¸Éϸ°ûÒÆÖ²ÖÎÁÆÐÂÕï¶ÏPh+¼±ÐÔÁܰÍϸ°û°×Ѫ²¡6ÀýÁÙ´²¹Û²ì [J] . ÖлªÑªÒºÑ§ÔÓÖ¾, 2023, 44(2) : 169-172.
Ã×Èð»ª, ³ÂÁÕ, Ñƽ, µÈ. ·úÂíÌæÄáÁªºÏ¶àµÏÍþ¹ú¼Ê»¯ÁÆÖÎÁÆPh+¼±ÐÔÁܰÍϸ°û°×Ѫ²¡12ÀýÁÆÐ§¼°°²È«ÐÔ·ÖÎö [J] . ÖлªÑªÒºÑ§ÔÓÖ¾, 2021, 42(10) : 858-861.
Wang Weimin et al. ESMO 2024 FPN£º829P: Flumatinib combined with chemotherapy for newly diagnosed adult with Ph-positive acute lymphoblastic leukemia£ºa single-center, retrospective observational study.
µÏÍþÖÆµÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖÆµÏÍþ¹ú¼ÊÆóÒµ£¬ÏÂÊôºÀɵÏÍþ¹ú¼ÊÒµ¡¢³£Öݺã°îµÏÍþ¹ú¼ÊÒµ¡¢µÏÍþÉúÎïÒ½µÏÍþ¹ú¼ÊµÈ×Ó¹«Ë¾£¬ÖØµã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò£¬ÖÂÁ¦ÓÚͨ¹ý³ÖÐø´´ÐÂÌá¸ßÈËÀàÉúÃüÖÊÁ¿¡£½ØÖÁ2024ÉϰëÄ꣬¹«Ë¾ÒÑÉÏÊÐ7¿î´´ÐµÏÍþ¹ú¼Ê£¬´´Ð²úÆ·ÓªÊÕÕ¼±È´ï77.4%¡£¹«Ë¾Á¬Ðø¶àÄêλ¾ÓÈ«ÇòÖÆµÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖØµã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£¹«Ë¾ÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£¸ü¶àÐÅÏ¢Çë·ÃÎÊ£º/¡£
±¾ÎÄÖ¼ÔÚÌṩÓйء°µÏÍþÖÆµÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¡±»òÆä×Ó¹«Ë¾µÈ¹ØÁª·½£¨Í³³Æ¡°¹«Ë¾¡±£©µÄÏà¹ØÐÅÏ¢£¬²»¹¹³É¹«Ë¾ÐÅÏ¢Åû¶»òͶ×ÊÍÆ¼ö¡£
±¾ÎÄËù·¢²¼µÄÐÅÏ¢ÖпÉÄÜ»á°üº¬Ä³Ð©Ç°Õ°ÐÔ±íÊö£¬ÀýÈçÉæ¼°ÒµÎñºÍ²úƷǰ¾°£¬»ò¹«Ë¾¼Æ»®¡¢ÈÏÖª¡¢Ô¤ÆÚ¼°²ßÂÔ¡£ÕâЩ±íÊöÊǽ¨Á¢ÔÚÍÆ²âÐÔ¼ÙÉèµÄÊý¾Ý»ù´¡ÉϵÄÔ¤²â£¬²¢·ÇÊǶÔδÀ´·¢Õ¹µÄ±£Ö¤£¬ÒòÆäÐÔÖÊʹȻ¾ùÊÜÏà¹Ø·çÏպͲ»È·¶¨ÒòËØÓ°Ï죬ÆäÖв¿·Ö»¹²»Êܹ«Ë¾¿ØÖÆÇÒÄÑÒÔÔ¤ÁÏ£¬Í¶×ÊÕß½øÐÐͶ×ʾö²ßʱӦ½÷É÷ʹÓá£ÔÚʹÓá°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°ÆÚÍû¡±¼°ÆäËûÀàËÆ´ÊÓï½øÐбíÊöʱ£¬·²Ó빫˾ÓйصÄÐÅÏ¢±íÊö£¬¾ùÊôÓÚǰհÐÔ±íÊö¡£¹«Ë¾²¢ÎÞÒåÎñ¸üлòÐÞ¸ÄÕâЩǰհÐÔ±íÊö£¬¹«Ë¾¡¢¹«Ë¾¶Ê¡¢¹ÍÔ±¡¢´úÀí¸Å²»³Ðµ£ÒòÈκÎǰհÐÔ±íÊö²»ÄÜʵÏÖ»ò±ä³É²»ÕýÈ·¶øÒýÖµÄÈκÎÔðÈΡ£
±¾ÐÂΟåÖеÄËùÓÐÐÅÏ¢½ö¼°ÓÚÐÂΟ巢²¼Ö®ÈÕ£¬ÎÞÂÛÊÇ·ñ³öÏÖÐÂ×ÊÁÏ¡¢Î´À´Ê¼þ»òÆäËûÇé¿ö£¬³ý·Ç·¨ÂÉÒªÇ󣬹«Ë¾²¢ÎÞÔðÈλòÒåÎñ¸üлòÐ޸ĸõÈÐÅÏ¢¡£Í¶×ÊÕßÒ˲ÎÕÕµÏÍþÖÆµÏÍþ¹ú¼Ê£¨03692.HK£©¹«¸æ¼°²Æ±¨£¬ÒÔ»ñÈ¡½öÓëÉÏÊй«Ë¾ÓйصÄÐÅÏ¢¡£